Company Research Report: EBAMed SA

Company Overview

• Name: EBAMed SA

• Mission: To enable safe and effective non-invasive treatments of heart arrhythmias with proton therapy.

• Founded By: No information is available.

• Key People:

• Marina Izzo – Chief Executive Officer (CEO)

• Adriano Garonna – Chief Technology Officer (CTO)

• Headquarters: Geneva, Switzerland

• Number of Employees: No information is available.

• Revenue: No information is available.

• Known For: Developing innovative solutions for non-invasive and painless treatment of heart arrhythmias using radio-therapy (external beam ablation).

Products

Main Product: CardioKit

• Description: An integrated system containing hardware and software for real-time guidance of proton beams to treat heart arrhythmias non-invasively.

• Key Features:

• Utilizes deep-learning algorithms to monitor and react to cardiac movement, including heart-beat, respiratory motion, and unpredictable changes.

• Consists of hardware for non-invasive heart motion imaging and synchronization of therapeutic beams.

• Provides a gating signal generator for precise beam delivery synchronization.

Recent Developments

• New Products Launched:

• CardioKit – A disruptive medical device to enable proton therapy as an automated treatment for heart arrhythmias.

• New Features:

• Development of device that automatically interprets cardiac ultrasound images to track heart motion for guiding proton therapy systems.

• Optimized software and miniaturized equipment for expanded market potential.

• Recent Partnerships and Achievements:

• Received EUR 2.4 million in funding from the European Commission under the Horizon 2020 EIC Accelerator Program.

• Secured EUR 14.35 million in Series A funding led by Panakès Partners, EIC Fund, among others, to advance cardiac radiation ablation therapy.

• Established partnerships with several clinical institutions like San Matteo Hospital (Italy), CNAO (Italy), Innovation Hub (Switzerland), UZ Leuven (Belgium), UPenn (USA), and Mayo Clinic (USA).

• Innovative Progress:

• Successfully completed pre-clinical and clinical studies in collaboration with prestigious institutions.

• Achieved completion of feasibility testing and development of minimum viable product.

• Held multiple US Patent grants and pending applications emphasizing device innovation.

• Clinical and Research Milestones:

• Enrolled first patient in a prospective imaging study using a cardiac ultrasound guidance prototype.

• Embarked on pre-clinical tests at Mayo Clinic Business Accelerator, ensuring a U.S. presence.

Additional Information

• Project ID: Nr. 954783 – EIC Accelerator Program

• Project Action: Development of CardioKit for non-invasive treatment of heart arrhythmias using proton therapy.

• Research Collaborations: Published results in Frontiers in Cardiovascular Medicine showcasing groundbreaking advancements in cardiac health interventions.

This report encapsulates the critical aspects of EBAMed SA's current operations, products, and strategic initiatives, highlighting their pioneering approach in advancing healthcare technologies for cardiovascular treatments.